The biotech firm reports $234 million in cash extending through 2029, supporting its upcoming RESCUE Phase 3 study.
Relmada Therapeutics announced a $234 million cash runway, sufficient to fund operations through 2029. The funds will support the mid-2026 launch of its Phase 3 RESCUE trial for NDV-01, a key pipeline asset.
The company recently completed a $160 million private financing round, bolstering its liquidity position. Management highlighted strong 12-month data for NDV-01, reinforcing confidence in the drug’s potential.
No immediate market reaction was disclosed, but the extended runway reduces near-term financing risks for investors.